Biogen (BIIB) experiences a seesaw performance over the years. Q1 earnings from Wedbush and predictions of the company's bullish behavior come in light of the EU approval for Leqembi, Biogen’s Alzheimer’s drug. The company, alongside partner Eisai, is soaring in stock, up 5.7% with potential for further growth. The company also sees robust purchasing of their shares by various asset management firms. Q1 2025 earnings call webcast surpasses estimates due to cost cuts and new drugs, although profit outlook falls short. Biogen boldly moves to transform the Kendall Square Research Hub into a 580,000 sq ft innovation powerhouse. Despite this, Biogen's five-year trend sees a shedding of US$697 million and declining investor returns. The company's Q4 results cause analysts to feel unsure about its prospects as profit drops. Despite setbacks, it receives US FDA fast track for Alzheimer's drug. However, the stock is downgraded and is seen as high risk. Argus Research maintains unhealthy outlook for Biogen's Q2 earnings because of lower expected revenue. Biogen shocks investors with surprising boost from their Alzheimer’s drug which, although reflects positively on sales, was not enough to prevent the stock from sinking.
Biogen BIIB News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Sat, 19 Apr 2025 10:58:49 GMT -
Rating 2
- Innovation 5
- Information 8
- Rumor 4
